Surfing the MASH Tsunami
Health & Wellness Podcasts
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Location:
United States
Genres:
Health & Wellness Podcasts
Description:
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Twitter:
@HepDynamics
Language:
English
Contact:
(215) 262-4658
Website:
https://surfingnash.com/
S5 - E7.6 - MASLD Patient Advocates' Recommendations for Others after Rezdiffra Approval
Duration:00:09:28
S5 - E7.5 - Will Increasing the Focus on MASH via Rezdiffra Overwhelm the Healthcare System?
Duration:00:11:11
S5 - E7.4 - How MASH patient advocates plan to support Rezdiffra
Duration:00:11:50
S5 - E7.3 - Patient advocacy and the Rezdiffra label
Duration:00:10:14
S5 - E7.1 - Rezdiffra is approved! How patient and their advocates processed the news about the first MASH drug
Duration:00:13:40
S5 - E7.2 - Identifying the target MASH patients for Rezdiffra
Duration:00:09:37
S5 - E7 - MASLD Patient Advocates Celebrate Rezdiffra and Discuss the Future
Duration:01:05:56
S5 - E6.6 - Closing Question From The Episode On Rezdiffra, The First MASH Drug
Duration:00:08:51
S5 - E6.5 - BioPharma Industry Takeaways ForBioPharma Industry Takeaways From The Rezdiffra Launch The Rezdiffra Launch
Duration:00:07:43
S5 - E6.4 - Finding The MASH Patients That Are The Initial Rezdiffra Targets
Duration:00:12:55
S5 - E6.3 - Staging and screening patients for Rezdiffra using NITs
Duration:00:15:15
S5 - E6.2 - How Approval Of Rezdiffra,The First MASH Drug, Might Improve Patient Adherence To Lifestyle Recommendations
Duration:00:11:56
S5 - E6.1 - Rezdiffra Is Approved! How Key Opinion Leaders Processed The News About The First MASH Drug
Duration:00:11:18
S5 - E6 - Rezdiffra Is Here! Key Opinion Leaders React To The First MASH Drug Approval
Duration:01:04:43
S5 - E5.6 - From The Vault: Tsunami's First Look At MASEF, A Major New NIT
Duration:00:13:46
S5 - E5.5 - More on GLP-1s and a Broader MASH Wrap-up
Duration:00:11:28
S5 - E5.4 - The dance of drug pricing and patient targets in MASH, PLUS: the role of GLP-1s
Duration:00:11:22
S5 - E5.3 - Strategies to Improve NIT reliability in Diagnosing and Staging MASH Fibrosis
Duration:00:14:56
S5 - E5.2 - NITs In The Diagnosis and Treatment Of Advanced MASH Fibrosis Patients
Duration:00:12:42
S5 - E5.1 - Why We Are Focusing On NITs For MASH Diagnosis And Screening
Duration:00:08:56